Life Science Instrumentation Market: Increasing Public–Private Investments In Life Science Research
Seeking Alpha Analyst Since 2014
#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology
- The global life science instrumentation market size is projected to reach USD 79.9 billion by 2025 from USD 60.0 billion in 2020, growing at a CAGR of 5.9% during the.
The report "Life Science Instrumentation Market by Technology [Spectroscopy, Chromatography, Flow Cytometry, NGS, PCR,, Microscopy], Application (Research, Clinical), End User (Pharma-Biotech, Agri and Food Industry, Hospitals & Diagnostic Labs) - Global Forecasts to 2025" The global life science instrumentation market size is projected to reach USD 79.9 billion by 2025 from USD 60.0 billion in 2020, growing at a CAGR of 5.9% during the forecast period.
Browse 189 market data Tables and 33 Figures spread through 306 Pages and in-depth TOC on "Life Science Instrumentation Market by Technology [Spectroscopy, Chromatography, Flow Cytometry, NGS, PCR,, Microscopy], Application (Research, Clinical), End User (Pharma-Biotech, Agri and Food Industry, Hospitals & Diagnostic Labs)-Global Forecasts to 2025" View detailed Table of Content here - Life Science Instrumentation Market
Increasing spending on pharmaceutical R&D, growing food safety concerns, technological advancements in analytical instruments, and the availability of funding for life science research are fueling the growth of the market. Moreover, rising environmental safety concerns, increasing demand for analytical instruments in several industries, and high demand in emerging nations are some of the other major factors driving the growth of this market.
The spectroscopy segment accounted for the largest share of the life science instrumentation market, by technology, in 2019
Based on technology, the market is segmented into spectroscopy, chromatography, PCR, immunoassays, lyophilization, liquid handling, clinical chemistry analyzers, microscopy, flow cytometry, next-generation sequencing (NGS), centrifuges, electrophoresis, cell counting, and other technologies. The spectroscopy technology segment accounted for the largest share of the life science instrumentation market during the forecast period.
Next-generation sequencing (NGS) to register the highest growth over the forecast period among life science instrumentation technologies
The Next-generation sequencing (NGS) segment is expected to register the highest growth over the forecast among the life science research market over the forecast period. The significant growth of this segment is attributed to the advantages offered by NGS technologies in DNA sequencing, which substantially provides more throughput and minimizes the need for fragment-cloning methods.
North America to dominate the life science instrumentation market during the forecast period
The life science instrumentation industry is segmented into five regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American region accounted for the largest share of the life science instrumentation market in 2019.
The high adoption rate of novel technologies and the large number of life science research studies conducted in this region. Moreover, stringent drug development regulations, increased funding for life science research activities, and the growing number of metabolomics research studies are some of the major factors driving the growth of the life science instrumentation sector in North America.
Request a Sample Pages @ Life Science Instrumentation Market
Agilent Technologies (US), Becton, Dickinson, and Company (US), Bio-Rad Laboratories, Inc. (US), Bruker Corporation (US), Danaher Corporation (US), Eppendorf AG (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Horiba (Japan), Merck KGaA (Germany), PerkinElmer, Inc.. (US), Qiagen N.V. (Netherlands), Shimadzu Corporation (Japan), Thermo Fisher Scientific, Inc. (US), and Waters Corporation (US).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.